Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development

Oncogene

Volumn 31, Issue 11, 2012, Pages 1459-1467

  Pyonteck, S M ^a,b   Gadea, B B ^a   Wang, H W ^a,b   Gocheva, V ^a,b   Hunter, K E ^a   Tang, L H ^a   Joyce, J A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

cancer; human PNET; myeloid cell; tumor microenvironment; tumor associated macrophage

Indexed keywords

CD68 ANTIGEN; COLONY STIMULATING FACTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GRADING; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; LIVER METASTASIS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN DEFECT; TUMOR GROWTH; TUMOR VOLUME;

ADENOMA, ISLET CELL; ANIMALS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICE; MICE, TRANSGENIC; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

ANIMALIA; MUS;

EID: 84858339905     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.337     Document Type: Article

References (41)

1. Abboud SL, Woodruff K, Liu C, Shen V, Ghosh-Choudhury N. (2002). Rescue of the osteopetrotic defect in op/op mice by osteoblast-specific targeting of soluble colony-stimulating factor-1.Endocrinology 143: 1942-1949.
2. Banaei-Bouchareb L, Gouon-Evans V, Samara-Boustani D, Castellotti MC, Czernichow P, Pollard JW et al. (2004). Insulin cell mass is altered in Csf1op/Csf1op macrophage-deficient mice. J Leukoc Biol 76: 359-367.
3. Bingle L, Brown NJ, Lewis CE. (2002). The role of tumour-Associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196: 254-265.
4. Chitu V, Stanley ER. (2006). Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 18: 39-48.
5. Chiu CW, Nozawa H, Hanahan D. (2010). Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 28: 4425-4433.
6. Christofori G, Naik P, Hanahan D. (1995). Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 9: 1760-1770.
7. Gocheva V, Chen X, Peters C, Reinheckel T, Joyce JA. (2010a). Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer. Biol Chem 391: 937-945.
8. Gocheva V, Wang H-W, Gadea BB, Shree T, Hunter KE, Garfall AL et al. (2010b). IL-4 induces cathepsin protease activity in tumorassociated macrophages to promote cancer growth and invasion. Genes Dev 24: 241-255.
9. Greenbaum D, Baruch A, Hayrapetian L, Darula Z, Burlingame A, Medzihradszky KF et al. (2002). Chemical approaches for functionally probing the proteome. Mol Cell Proteomics 1: 60-68.
10. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. (2008). Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer 15: 409-427.
11. Hamilton JA. (2008). Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8: 533-544.
12. Hanahan D. (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122.
13. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70.
14. Hu W, Feng Z, Modica I, Klimstra DS, Song L, Allen PJ et al. (2010). Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway. Genes Cancer 1: 360-368.
15. Joyce JA, Pollard JW. (2009). Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
16. Köhler C. (2007)Allograft inflammatory factor-1/ionized calciumbinding adapter molecule 1 is specifically expressed by most subpopulations of macrophages and spermatids in testis. Cell Tissue Res 330: 291-302.
17. Lewis CE, Pollard JW. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
18. Lin EY, Li J-f, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA et al. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246.
19. Lin EY, Li J-f, Bricard G, Wang W, Deng Y, Sellers R et al. (2007). Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol 1: 288-302.
20. Lin EY, Nguyen AV, Russell RG, Pollard JW. (2001). Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740.
21. Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E et al. (2008). Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320: 807-811.
22. Lopez T, Hanahan D. (2002). Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1: 339-353.
23. Macdonald KPA, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC et al. (2010). An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-Associated macrophages but does not inhibit inflammation. Blood 116: 3955-3963.
24. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. (2010). The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21: 27-39.
25. Nozawa H, Chiu C, Hanahan D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103: 12493-12498.
26. Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S et al. (2008). Activated macrophages promote Wnt signalling through tumour necrosis factor-A in gastric tumourtumor cells. EMBO J 27: 1671-1681.
27. Pahler JC, Tazzyman S, Erez N, Chen Y-Y, Murdoch C, Nozawa H et al. (2008). Plasticity in tumor-promoting inflammation: Impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10: 329-340.
28. Pietras K, Hanahan D. (2005). A multitargeted, metronomic, and maximum-tolerated dose 00chemo-switch00 regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939-952.
29. Qian B-Z, Pollard JW. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
30. Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard- Bohas C et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513.
31. Reidy DL, Tang LH, Saltz LB. (2009). Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol 6: 143-152.
32. Robinson BD, Sica GL, Liu Y-F, Rohan TE, Gertler FB, Condeelis JS et al. (2009). Tumor microenvironment of metastasis in human breast carcinoma: A potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 15: 2433-2441.
33. Ryder M, Ghossein RA, Ricarte-Filho JCM, Knauf JA, Fagin JA. (2008). Increased density of tumor-Associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15: 1069-1074.
34. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. (2005). PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7: 870-879.
35. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T et al. (2010). Tumor-Associated macrophages and survival in classic Hodgkin0s lymphoma. N Engl J Med 362: 875-885.
36. Steiner GE, Ecker RC, Kramer G, Stockenhuber F, Marberger MJ. (2000). Automated data acquisition by confocal laser scanning microscopy and image analysis of triple stained immunofluorescent leukocytes in tissue. J Immunol Methods 237: 39-50.
37. Tuveson D, Hanahan D. (2011). Translational medicine: Cancer lessons from mice to humans. Nature 471: 316-317.
38. Wei S, Nandi S, Chitu V, Yeung Y-G, Yu W, Huang M et al. (2010). Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol 88: 495-505.
39. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW, Ahmed-Ansari A, Sell KW, Pollard JW et al. (1990). Total absence of colonystimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 87: 4828-4832.
40. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.
41. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H et al. (1990). The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345: 442-444.